$SILK
Silk Road Medical Inc

2019 Q3 Form 10-Q Financial Statement

#000139770219000015 Filed on August 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2018 Q2
Revenue $17.03M $14.93M $7.767M
YoY Change 77.1% 92.2%
Cost Of Revenue $4.170M $3.697M $2.391M
YoY Change 44.69% 54.62%
Gross Profit $12.86M $11.23M $5.376M
YoY Change 90.97% 108.91%
Gross Profit Margin 75.51% 75.23% 69.22%
Selling, General & Admin $17.06M $14.14M $7.816M
YoY Change 90.17% 80.85%
% of Gross Profit 132.73% 125.86% 145.39%
Research & Development $3.187M $3.113M $2.326M
YoY Change 30.51% 33.83%
% of Gross Profit 24.79% 27.72% 43.27%
Depreciation & Amortization $180.0K $180.0K $70.00K
YoY Change -10.0% 157.14%
% of Gross Profit 1.4% 1.6% 1.3%
Operating Expenses $20.25M $17.25M $10.14M
YoY Change 77.41% 70.07%
Operating Profit -$7.395M -$6.017M -$4.766M
YoY Change 57.91% 26.25%
Interest Expense $1.176M $1.207M $1.011M
YoY Change 10.42% 19.39%
% of Operating Profit
Other Income/Expense, Net -$1.000K -$5.333M -$1.898M
YoY Change -99.97% 180.98%
Pretax Income -$8.010M -$11.96M -$7.650M
YoY Change -10.5% 56.34%
Income Tax
% Of Pretax Income
Net Earnings -$8.007M -$11.96M -$7.651M
YoY Change -10.56% 56.31%
Net Earnings / Revenue -47.03% -80.11% -98.51%
Basic Earnings Per Share
Diluted Earnings Per Share -$260.4K -$388.9K -$253.1K
COMMON SHARES
Basic Shares Outstanding 30.76M shares 30.67M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $112.3M $118.2M
YoY Change
Cash & Equivalents $112.3M $118.2M $23.33M
Short-Term Investments
Other Short-Term Assets $3.500M $3.200M
YoY Change
Inventory $9.275M $8.963M
Prepaid Expenses
Receivables $6.932M $5.417M
Other Receivables $0.00 $0.00
Total Short-Term Assets $132.0M $135.9M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $2.697M $2.743M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.575M $3.723M
YoY Change
Total Long-Term Assets $6.582M $6.776M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $132.0M $135.9M
Total Long-Term Assets $6.582M $6.776M
Total Assets $138.6M $142.7M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.965M $1.189M
YoY Change
Accrued Expenses $10.48M $8.299M
YoY Change
Deferred Revenue $335.0K $257.0K
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.44M $9.488M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $44.79M $44.69M
YoY Change
Other Long-Term Liabilities $3.900M $4.097M
YoY Change
Total Long-Term Liabilities $48.69M $48.79M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $12.44M $9.488M
Total Long-Term Liabilities $48.69M $48.79M
Total Liabilities $61.13M $58.28M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$183.2M -$175.2M
YoY Change
Common Stock $31.00K $31.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $77.44M $84.38M -$110.6M
YoY Change
Total Liabilities & Shareholders Equity $138.6M $142.7M
YoY Change

Cashflow Statement

Concept 2019 Q3 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income -$8.007M -$11.96M -$7.651M
YoY Change -10.56% 56.31%
Depreciation, Depletion And Amortization $180.0K $180.0K $70.00K
YoY Change -10.0% 157.14%
Cash From Operating Activities -$6.350M -$9.380M -$5.290M
YoY Change -0.31% 77.32%
INVESTING ACTIVITIES
Capital Expenditures -$130.0K -$90.00K -$540.0K
YoY Change -88.89% -83.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$130.0K -$90.00K -$540.0K
YoY Change -88.89% -83.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 500.0K 112.2M 150.0K
YoY Change -96.71% 74706.67%
NET CHANGE
Cash From Operating Activities -6.350M -9.380M -5.290M
Cash From Investing Activities -130.0K -90.00K -540.0K
Cash From Financing Activities 500.0K 112.2M 150.0K
Net Change In Cash -5.980M 102.7M -5.680M
YoY Change -177.86% -1908.8%
FREE CASH FLOW
Cash From Operating Activities -$6.350M -$9.380M -$5.290M
Capital Expenditures -$130.0K -$90.00K -$540.0K
Free Cash Flow -$6.220M -$9.290M -$4.750M
YoY Change 19.62% 95.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36117000 USD
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Entity Central Index Key
EntityCentralIndexKey
0001397702
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
29879220 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1135310 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1135310 shares
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30747714 shares
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5408000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7651000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13058000 USD
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24158000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11959000 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2019Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2561000 USD
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.3704
CY2019Q2 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0 USD
CY2018Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0 shares
CY2019Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2018Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
21233190 shares
CY2019Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38847
dei Entity Address Address Line1
EntityAddressAddressLine1
1213 Innsbruck Dr.
dei Entity Address City Or Town
EntityAddressCityOrTown
Sunnyvale
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94089
dei City Area Code
CityAreaCode
408
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Local Phone Number
LocalPhoneNumber
720-9002
CY2018Q4 us-gaap Liabilities
Liabilities
70199000 USD
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
dei Entity Registrant Name
EntityRegistrantName
SILK ROAD MEDICAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8777622
dei Entity Shell Company
EntityShellCompany
false
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
dei Security12b Title
Security12bTitle
Common Stock
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 USD
dei Entity Small Business
EntitySmallBusiness
true
CY2018Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
105235000 USD
dei Trading Symbol
TradingSymbol
SILK
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30761483 shares
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
118247000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24990000 USD
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5417000 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4520000 USD
CY2019Q2 us-gaap Inventory Net
InventoryNet
8963000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
5744000 USD
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3249000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1408000 USD
CY2019Q2 us-gaap Assets Current
AssetsCurrent
135876000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
36662000 USD
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2743000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2880000 USD
CY2019Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
310000 USD
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
310000 USD
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3723000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1029000 USD
CY2019Q2 us-gaap Assets
Assets
142652000 USD
CY2018Q4 us-gaap Assets
Assets
40881000 USD
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1189000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1252000 USD
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8299000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7586000 USD
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9488000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8838000 USD
CY2019Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
44690000 USD
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
44201000 USD
CY2019Q2 silk Preferred Stock Warrant Liability
PreferredStockWarrantLiability
0 USD
CY2018Q4 silk Preferred Stock Warrant Liability
PreferredStockWarrantLiability
16091000 USD
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4097000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1069000 USD
CY2019Q2 us-gaap Liabilities
Liabilities
58275000 USD
CY2019Q2 us-gaap Gross Profit
GrossProfit
11231000 USD
CY2018Q2 us-gaap Gross Profit
GrossProfit
5376000 USD
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
us-gaap Gross Profit
GrossProfit
20659000 USD
us-gaap Gross Profit
GrossProfit
9148000 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
364000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3113000 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2326000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5820000 USD
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
31000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1000 USD
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
259574000 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4557000 USD
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-175228000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-139111000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
84377000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-134553000 USD
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
142652000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40881000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14928000 USD
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7767000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27694000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13473000 USD
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3697000 USD
CY2018Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2391000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7035000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4325000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4426000 USD
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14135000 USD
CY2018Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7816000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
28001000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14135000 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
17248000 USD
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
10142000 USD
us-gaap Operating Expenses
OperatingExpenses
33821000 USD
us-gaap Operating Expenses
OperatingExpenses
18561000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6017000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4766000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13162000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-9413000 USD
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
598000 USD
CY2018Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
24000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
650000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
375000 USD
CY2019Q2 silk Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
31000 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
839229 shares
CY2019Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
144140000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-134553000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-158074000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
37000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
1207000 USD
CY2018Q2 us-gaap Interest Expense
InterestExpense
1011000 USD
us-gaap Interest Expense
InterestExpense
2560000 USD
us-gaap Interest Expense
InterestExpense
2000000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5333000 USD
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1898000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-21045000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1682000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-11959000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-7651000 USD
us-gaap Net Income Loss
NetIncomeLoss
-36117000 USD
us-gaap Net Income Loss
NetIncomeLoss
-13058000 USD
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.16
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.42
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-15.56
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28458793 shares
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
938052 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14905052 shares
CY2019Q1 silk Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
0 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
241000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
21000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-24158000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
84377000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-98578000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
170000 USD
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
284000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
478000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-11959000 USD
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
109039000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
814000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
22000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
164000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
-2000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-756000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-5408000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
46000 USD
silk Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
300000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
52000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-45000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
555000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
782000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
24000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
377000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
724000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
663000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-103453000 USD
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
148000 USD
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
178000 USD
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
151000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-7651000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-110627000 USD
us-gaap Net Income Loss
NetIncomeLoss
-36117000 USD
us-gaap Net Income Loss
NetIncomeLoss
-13058000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
350000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
131000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1099000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
491000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
21030000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1678000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
22000 USD
us-gaap Inventory Write Down
InventoryWriteDown
43000 USD
us-gaap Inventory Write Down
InventoryWriteDown
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1622000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-475000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3262000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1054000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1841000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-372000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
244000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18003000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9938000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
206000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1004000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-206000 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
108913000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
738000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1004000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
432000 USD
silk Stock Issuance Costs Incurred But Not Yet Paid
StockIssuanceCostsIncurredButNotYetPaid
358000 USD
silk Stock Issuance Costs Incurred But Not Yet Paid
StockIssuanceCostsIncurredButNotYetPaid
0 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23331000 USD
us-gaap Interest Paid Net
InterestPaidNet
1982000 USD
us-gaap Interest Paid Net
InterestPaidNet
1172000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
696000 USD
us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
0 USD
us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
794000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
111466000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
432000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
93257000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10510000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25300000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33841000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
118557000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3982000 USD
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
37121000 USD
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
144140000 USD
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to the common stock valuation and related stock-based compensation, the valuation of the redeemable convertible preferred stock warrants, the valuation of deferred tax assets, provisions for doubtful accounts receivable and excess and obsolete inventories, clinical trial accruals, and the reserves for sales returns. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div>
CY2019Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
310000 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;font-weight:bold;">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable to the extent of the amounts recorded on the condensed consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;">The Company’s policy is to invest in money market funds, which are classified as cash equivalents on the condensed consolidated balance sheet. The Company's cash is held in Company accounts at two financial institutions and such amounts may exceed federally insured limits. The Company's money market funds are invested in highly rated money market funds. </span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;">The Company provides for uncollectible amounts when specific credit problems are identified. In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;">The Company’s accounts receivable are due from a variety of health care organizations in the United States. At </span><span style="font-family:Arial;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial;font-size:10pt;color:#000000;">December 31, 2018</span><span style="font-family:Arial;font-size:10pt;color:#000000;">, </span><span style="font-family:Arial;font-size:10pt;color:#000000;">no</span><span style="font-family:Arial;font-size:10pt;color:#000000;"> customer represented 10% or more of the Company’s accounts receivable. For the three and six months ended </span><span style="font-family:Arial;font-size:10pt;color:#000000;">June 30, 2019</span><span style="font-family:Arial;font-size:10pt;color:#000000;"> and </span><span style="font-family:Arial;font-size:10pt;color:#000000;">June 30, 2018</span><span style="font-family:Arial;font-size:10pt;color:#000000;">, there were </span><span style="font-family:Arial;font-size:10pt;color:#000000;">no</span><span style="font-family:Arial;font-size:10pt;color:#000000;"> customers that represented 10% or more of revenue. </span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;">The Company manufactures certain of its commercial products in-house. Certain of the Company’s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE stent. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#000000;">Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company’s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.</span></div>
CY2019Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0 USD
CY2018Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
950000 USD
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3982000 USD
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
721000 USD
CY2019Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4469000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
144140000 USD
CY2019Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
161000 USD
CY2018Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
128000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-11959000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-7651000 USD
us-gaap Net Income Loss
NetIncomeLoss
-36117000 USD
us-gaap Net Income Loss
NetIncomeLoss
-13058000 USD
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28458793 shares
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
938052 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14905052 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
839229 shares
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.16
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.42
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-15.56
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4683811 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28239292 shares
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2018Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
16091000 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-21030000 USD
silk Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassifications
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassifications
37121000 USD
CY2019Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0 USD
CY2019Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
866000 USD
CY2018Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1054000 USD
CY2019Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
8097000 USD
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4690000 USD
CY2019Q2 us-gaap Inventory Net
InventoryNet
8963000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
5744000 USD
CY2019Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0 USD
CY2019Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4609000 USD
CY2018Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
5157000 USD
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1024000 USD
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1014000 USD
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
730000 USD
CY2019Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
389000 USD
CY2018Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
313000 USD
CY2019Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
257000 USD
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
137000 USD
CY2019Q2 silk Accrued Travel Expenses Current
AccruedTravelExpensesCurrent
443000 USD
CY2018Q4 silk Accrued Travel Expenses Current
AccruedTravelExpensesCurrent
270000 USD
CY2019Q2 silk Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
354000 USD
CY2018Q4 silk Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
244000 USD
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
493000 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
451000 USD
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8299000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7586000 USD
CY2018Q3 silk Debt Maximum Borrowing Capacity
DebtMaximumBorrowingCapacity
15000000 USD
silk Debt Instrument Covenant Maximum Liquidity Amount
DebtInstrumentCovenantMaximumLiquidityAmount
3000000 USD
CY2016 silk Debt Instrument Covenant Minimum Net Revenue Amount
DebtInstrumentCovenantMinimumNetRevenueAmount
1000000 USD
CY2017 silk Debt Instrument Covenant Minimum Net Revenue Amount
DebtInstrumentCovenantMinimumNetRevenueAmount
5000000 USD
CY2018 silk Debt Instrument Covenant Minimum Net Revenue Amount
DebtInstrumentCovenantMinimumNetRevenueAmount
15000000 USD
silk Debt Instrument Liquidity Covenant Term
DebtInstrumentLiquidityCovenantTerm
P90D
CY2019Q2 us-gaap Long Term Debt
LongTermDebt
44690000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
434000000 USD
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
169000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
363000000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1066000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1096000 USD
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
2239000 USD
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4454000 USD
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
4442000 USD
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
48256000 USD
CY2019Q2 silk Long Term Debt Gross Before Accretion Of Closing Fees
LongTermDebtGrossBeforeAccretionOfClosingFees
59391000 USD
CY2019Q2 silk Long Term Debt Accretion Of Closing Fees
LongTermDebtAccretionOfClosingFees
1040000 USD
CY2019Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
60431000 USD
CY2019Q2 silk Long Term Debt Unpaid Interest
LongTermDebtUnpaidInterest
15578000 USD
CY2019Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
163000 USD
CY2019Q2 us-gaap Long Term Debt
LongTermDebt
44690000 USD
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
217000 USD
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0650
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y3M29D
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3683000 USD
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
730000 USD
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4097000 USD
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4827000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
510000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1037000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1127000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
904000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5740000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
913000 USD
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4827000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1920000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
5999000 USD
CY2019Q2 us-gaap Purchase Obligation
PurchaseObligation
1448000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1002000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1002000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1031000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1044000 USD
CY2018Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
24069615 shares
CY2018Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
21233190 shares
CY2018Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
121144000 USD
CY2018Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
105235000 USD
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30747714 shares
us-gaap Dividends Common Stock
DividendsCommonStock
0 USD
silk Common Stock Vote Per Share
CommonStockVotePerShare
1 vote
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
57889 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4364377 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.79
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M9D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
33132000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
2317000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
757108 shares
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
195326000 USD
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2493493 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y6M
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
195326000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
9077000 USD
CY2019Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
8683000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M29D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
757108 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
20.97
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
427881 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
9793 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
9793 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.99
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1627574 shares
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4683811 shares
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.76
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.09
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M9D
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
113136000 USD
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4383811 shares
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.76
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
836000 USD
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
329000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1099000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
491000 USD

Files In Submission

Name View Source Status
0001397702-19-000015-index-headers.html Edgar Link pending
0001397702-19-000015-index.html Edgar Link pending
0001397702-19-000015.txt Edgar Link pending
0001397702-19-000015-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
q22019exhibit311.htm Edgar Link pending
q22019exhibit312.htm Edgar Link pending
q22019exhibit321.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
silk-20190630.xsd Edgar Link pending
silk-20190630_cal.xml Edgar Link unprocessable
silk-20190630_def.xml Edgar Link unprocessable
silk-20190630_lab.xml Edgar Link unprocessable
silk-20190630_pre.xml Edgar Link unprocessable
silkroad10-q630.htm Edgar Link pending
silkroad10-q630_htm.xml Edgar Link completed